Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102518 · ClinicalTrials.gov registry record · Phase 3
Aripiprazole Open-Label, Safety and Tolerability Study
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 325
- Enrollment target
NCT00102518 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 325 participants.
The verdict
NCT00102518, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 325 participants
- Enrollment target
Study Summary
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102518
The ClinicalTrials.gov registry entry for NCT00102518 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00102518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102518 about?
NCT00102518 is a clinical study titled "Aripiprazole Open-Label, Safety and Tolerability Study". The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
What is the current status of trial NCT00102518?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 325 participants. The study started on 2004-09. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00102518?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00102518?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.